Regenxbio (RGNX) Announces Additional Positive Interim Phase I/IIa Trial Update and Program Updates for RGX-314 for the Treatment of Wet AMD
Go back to Regenxbio (RGNX) Announces Additional Positive Interim Phase I/IIa Trial Update and Program Updates for RGX-314 for the Treatment of Wet AMD| Jennison Natural Resources Fund Class B (NASDAQ: RGNX) | Delayed: 7.98 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.98 | 52 Week High | $25.00 | |||
| Open | $7.98 | 52 Week Low | $7.07 | |||
| Day High | $7.98 | P/E | N/A | |||
| Day Low | $7.98 | EPS | $0.00 | |||
| Volume | 766 | |||||
